DDInter667 DDInter1008
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue to be used in topical formulations.
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Erlotinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Erlotinib {u} (Compound) downregulates {v} (Gene) HMGCS1
HMGCS1 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Erlotinib {u} (Compound) downregulates {v} (Gene) SLC35F2
SLC35F2 {u} (Gene) is downregulated by {v} (Compound) Ketoconazole
Erlotinib {u} (Compound) causes {v} (Side Effect) Hepatotoxicity
Hepatotoxicity {u} (Side Effect) is caused by {v} (Compound) Ketoconazole
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Erlotinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Erlotinib {u} (Compound) downregulates {v} (Gene) HMGCS1
HMGCS1 {u} (Gene) is regulated by {v} (Gene) SLC35F2
SLC35F2 {u} (Gene) is downregulated by {v} (Compound) Ketoconazole
Erlotinib {u} (Compound) downregulates {v} (Gene) SLC35F2
SLC35F2 {u} (Gene) is regulated by {v} (Gene) AR
AR {u} (Gene) is bound by {v} (Compound) Ketoconazole
Erlotinib {u} (Compound) causes {v} (Side Effect) Hepatotoxicity
Hepatotoxicity {u} (Side Effect) is caused by {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole (Compound) resembles Ketoconazole (Compound)
Erlotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ketoconazole (Compound)
Erlotinib (Compound) downregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Ketoconazole (Compound)
Erlotinib (Compound) downregulates SLC35F2 (Gene) and SLC35F2 (Gene) is downregulated by Ketoconazole (Compound)
Erlotinib (Compound) causes Hepatotoxicity (Side Effect) and Hepatotoxicity (Side Effect) is caused by Ketoconazole (Compound)
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole (Compound) resembles Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Erlotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Erlotinib (Compound) downregulates HMGCS1 (Gene) and HMGCS1 (Gene) is regulated by SLC35F2 (Gene) and SLC35F2 (Gene) is downregulated by Ketoconazole (Compound)
Erlotinib (Compound) downregulates SLC35F2 (Gene) and SLC35F2 (Gene) is regulated by AR (Gene) and AR (Gene) is bound by Ketoconazole (Compound)
Erlotinib (Compound) causes Hepatotoxicity (Side Effect) and Hepatotoxicity (Side Effect) is caused by Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)